Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electrophysiological effects of Irbesartan in patients with paroxysmal atrial fibrillation
2005-002809-23Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of irbesartan in Atrial fibrillation (AFib), sponsored by Bristol Myers Squibb. Primary endpoint: Atrial effective refractory period (AERP). Started Oct 2005; status: completed.
02
Drugs
irbesartan
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2005-002809-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002809-23.